ID   MRCKA_RAT               Reviewed;        1732 AA.
AC   O54874;
DT   08-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   24-JUL-2024, entry version 178.
DE   RecName: Full=Serine/threonine-protein kinase MRCK alpha;
DE            EC=2.7.11.1;
DE   AltName: Full=CDC42-binding protein kinase alpha;
DE   AltName: Full=Myotonic dystrophy kinase-related CDC42-binding kinase alpha;
DE            Short=MRCK alpha;
DE            Short=Myotonic dystrophy protein kinase-like alpha;
GN   Name=Cdc42bpa {ECO:0000250|UniProtKB:Q5VT25};
GN   Synonyms=Pk428 {ECO:0000312|RGD:621406};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAC02941.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-106.
RC   TISSUE=Brain {ECO:0000312|EMBL:AAC02941.1};
RX   PubMed=9418861; DOI=10.1128/mcb.18.1.130;
RA   Leung T., Chen X.-Q., Tan I., Manser E., Lim L.;
RT   "Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a Cdc42
RT   effector in promoting cytoskeletal reorganization.";
RL   Mol. Cell. Biol. 18:130-140(1998).
RN   [2] {ECO:0000305}
RP   OLIGOMERIZATION.
RX   PubMed=11283256; DOI=10.1128/mcb.21.8.2767-2778.2001;
RA   Tan I., Seow K.T., Lim L., Leung T.;
RT   "Intermolecular and intramolecular interactions regulate catalytic activity
RT   of myotonic dystrophy kinase-related Cdc42-binding kinase alpha.";
RL   Mol. Cell. Biol. 21:2767-2778(2001).
RN   [3]
RP   ALTERNATIVE SPLICING.
RX   PubMed=12568720; DOI=10.1016/s0378-1119(02)01185-x;
RA   Tan I., Cheong A., Lim L., Leung T.;
RT   "Genomic organization of human myotonic dystrophy kinase-related Cdc42-
RT   binding kinase alpha reveals multiple alternative splicing and functional
RT   diversity.";
RL   Gene 304:107-115(2003).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1127, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=16641100; DOI=10.1073/pnas.0600895103;
RA   Hoffert J.D., Pisitkun T., Wang G., Shen R.-F., Knepper M.A.;
RT   "Quantitative phosphoproteomics of vasopressin-sensitive renal cells:
RT   regulation of aquaporin-2 phosphorylation at two sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:7159-7164(2006).
RN   [5]
RP   FUNCTION, AND INTERACTION WITH MYO18A AND LURAP1.
RX   PubMed=18854160; DOI=10.1016/j.cell.2008.09.018;
RA   Tan I., Yong J., Dong J.M., Lim L., Leung T.;
RT   "A tripartite complex containing MRCK modulates lamellar actomyosin
RT   retrograde flow.";
RL   Cell 135:123-136(2008).
RN   [6]
RP   FUNCTION IN PHOSPHORYLATION OF PPP1R12A AND MYL9/MLC2, AND ACTIVITY
RP   REGULATION.
RX   PubMed=21457715; DOI=10.1016/j.febslet.2011.03.054;
RA   Tan I., Lai J., Yong J., Li S.F., Leung T.;
RT   "Chelerythrine perturbs lamellar actomyosin filaments by selective
RT   inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase.";
RL   FEBS Lett. 585:1260-1268(2011).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1651 AND SER-1721, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [8]
RP   INTERACTION WITH FAM89B AND LURAP1.
RC   TISSUE=Brain;
RX   PubMed=25107909; DOI=10.1074/jbc.m114.588079;
RA   Lee I.C., Leung T., Tan I.;
RT   "Adaptor protein LRAP25 mediates myotonic dystrophy kinase-related Cdc42-
RT   binding kinase (MRCK) regulation of LIMK1 protein in lamellipodial F-actin
RT   dynamics.";
RL   J. Biol. Chem. 289:26989-27003(2014).
CC   -!- FUNCTION: Serine/threonine-protein kinase which is an important
CC       downstream effector of CDC42 and plays a role in the regulation of
CC       cytoskeleton reorganization and cell migration (PubMed:9418861).
CC       Regulates actin cytoskeletal reorganization via phosphorylation of
CC       PPP1R12A and MYL9/MLC2 (PubMed:21457715). In concert with MYO18A and
CC       LURAP1, is involved in modulating lamellar actomyosin retrograde flow
CC       that is crucial to cell protrusion and migration (PubMed:18854160).
CC       Phosphorylates: PPP1R12C, LIMK1 and LIMK2. May play a role in TFRC-
CC       mediated iron uptake. In concert with FAM89B/LRAP25 mediates the
CC       targeting of LIMK1 to the lamellipodium resulting in its activation and
CC       subsequent phosphorylation of CFL1 which is important for lamellipodial
CC       F-actin regulation (By similarity). Triggers the formation of an
CC       extrusion apical actin ring required for epithelial extrusion of
CC       apoptotic cells (By similarity). {ECO:0000250|UniProtKB:Q3UU96,
CC       ECO:0000250|UniProtKB:Q5VT25, ECO:0000269|PubMed:18854160,
CC       ECO:0000269|PubMed:21457715, ECO:0000269|PubMed:9418861}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:9418861};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:9418861};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:9418861};
CC   -!- ACTIVITY REGULATION: Maintained in an inactive, closed conformation by
CC       an interaction between the kinase domain and the negative
CC       autoregulatory C-terminal coiled-coil region. Agonist binding to the
CC       phorbol ester binding site disrupts this, releasing the kinase domain
CC       to allow N-terminus-mediated dimerization and kinase activation by
CC       transautophosphorylation (By similarity). Inhibited by chelerythrine
CC       chloride. {ECO:0000250, ECO:0000269|PubMed:21457715}.
CC   -!- SUBUNIT: Homodimer and homotetramer via the coiled coil regions
CC       (PubMed:11283256). Interacts tightly with GTP-bound but not GDP-bound
CC       CDC42 (By similarity). Forms a tripartite complex with MYO18A and
CC       LURAP1 with the latter acting as an adapter connecting CDC42BPA and
CC       MYO18A. LURAP1 binding results in activation of CDC42BPA by abolition
CC       of its negative autoregulation (PubMed:18854160). Interacts with LURAP1
CC       (PubMed:25107909). Interacts (via AGC-kinase C-terminal domain) with
CC       FAM89B/LRAP25 (via LRR repeat) (PubMed:25107909). Forms a tripartite
CC       complex with FAM89B/LRAP25 and LIMK1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q3UU96, ECO:0000250|UniProtKB:Q5VT25,
CC       ECO:0000269|PubMed:11283256, ECO:0000269|PubMed:18854160,
CC       ECO:0000269|PubMed:25107909}.
CC   -!- INTERACTION:
CC       O54874; O54874: Cdc42bpa; NbExp=2; IntAct=EBI-689253, EBI-689253;
CC       O54874; D4A8G3: Lurap1; NbExp=8; IntAct=EBI-689253, EBI-2015467;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9418861}. Cell
CC       projection, lamellipodium {ECO:0000250|UniProtKB:Q3UU96}. Note=Displays
CC       a dispersed punctate distribution and concentrates along the cell
CC       periphery, especially at the leading edge and cell-cell junction. This
CC       concentration is PH-domain dependent (PubMed:9418861). Localizes in the
CC       lamellipodium in a FAM89B/LRAP25-dependent manner (By similarity).
CC       {ECO:0000250|UniProtKB:Q3UU96, ECO:0000269|PubMed:9418861}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1;
CC         IsoId=O54874-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O54874-2; Sequence=Not described;
CC       Name=3;
CC         IsoId=O54874-3; Sequence=Not described;
CC       Name=4;
CC         IsoId=O54874-4; Sequence=Not described;
CC       Name=5;
CC         IsoId=O54874-5; Sequence=Not described;
CC       Name=6;
CC         IsoId=O54874-6; Sequence=Not described;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the brain and lung and present
CC       in lower levels in all other tissues tested.
CC       {ECO:0000269|PubMed:9418861}.
CC   -!- PTM: Proteolytically cleaved by caspases upon apoptosis induction. The
CC       cleavage at Asp-478 by CASP3 increases its kinase activity (in vitro).
CC       {ECO:0000250|UniProtKB:Q5VT25}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. DMPK subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF021935; AAC02941.1; -; mRNA.
DR   PIR; T14039; T14039.
DR   RefSeq; NP_446109.1; NM_053657.1.
DR   PDB; 4AW2; X-ray; 1.70 A; A=2-424.
DR   PDBsum; 4AW2; -.
DR   AlphaFoldDB; O54874; -.
DR   SMR; O54874; -.
DR   IntAct; O54874; 8.
DR   MINT; O54874; -.
DR   STRING; 10116.ENSRNOP00000003837; -.
DR   CarbonylDB; O54874; -.
DR   iPTMnet; O54874; -.
DR   PhosphoSitePlus; O54874; -.
DR   jPOST; O54874; -.
DR   PaxDb; 10116-ENSRNOP00000003837; -.
DR   GeneID; 114116; -.
DR   KEGG; rno:114116; -.
DR   UCSC; RGD:621406; rat. [O54874-1]
DR   AGR; RGD:621406; -.
DR   CTD; 8476; -.
DR   RGD; 621406; Cdc42bpa.
DR   eggNOG; KOG0612; Eukaryota.
DR   InParanoid; O54874; -.
DR   OrthoDB; 988261at2759; -.
DR   PhylomeDB; O54874; -.
DR   Reactome; R-RNO-9013149; RAC1 GTPase cycle.
DR   Reactome; R-RNO-9013406; RHOQ GTPase cycle.
DR   EvolutionaryTrace; O54874; -.
DR   PRO; PR:O54874; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0042641; C:actomyosin; IDA:UniProtKB.
DR   GO; GO:0031252; C:cell leading edge; IDA:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; IBA:GO_Central.
DR   GO; GO:0030027; C:lamellipodium; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0031032; P:actomyosin structure organization; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; IDA:RGD.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; ISO:RGD.
DR   GO; GO:0007097; P:nuclear migration; ISO:RGD.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; IDA:UniProtKB.
DR   CDD; cd00132; CRIB; 1.
DR   CDD; cd01243; PH_MRCK; 1.
DR   CDD; cd05623; STKc_MRCK_alpha; 1.
DR   Gene3D; 1.10.287.1490; -; 1.
DR   Gene3D; 1.20.5.340; -; 1.
DR   Gene3D; 3.30.60.20; -; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR001180; CNH_dom.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR031597; KELK.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR026611; MRCK_alpha_cat.
DR   InterPro; IPR014930; Myotonic_dystrophy_kinase_coil.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR050839; Rho-assoc_Ser/Thr_Kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR22988; MYOTONIC DYSTROPHY S/T KINASE-RELATED; 1.
DR   PANTHER; PTHR22988:SF31; SERINE_THREONINE-PROTEIN KINASE MRCK ALPHA; 1.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF00780; CNH; 1.
DR   Pfam; PF08826; DMPK_coil; 1.
DR   Pfam; PF15796; KELK; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00036; CNH; 1.
DR   SMART; SM00285; PBD; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF57889; Cysteine-rich domain; 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   SUPFAM; SSF69322; Tricorn protease domain 2; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50219; CNH; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell projection;
KW   Coiled coil; Cytoplasm; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN           1..1732
FT                   /note="Serine/threonine-protein kinase MRCK alpha"
FT                   /id="PRO_0000086393"
FT   DOMAIN          77..343
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:9418861"
FT   DOMAIN          344..414
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          1082..1201
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          1227..1499
FT                   /note="CNH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00795"
FT   DOMAIN          1571..1584
FT                   /note="CRIB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00057"
FT   ZN_FING         1012..1062
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          973..1002
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1592..1732
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          437..670
FT                   /evidence="ECO:0000255"
FT   COILED          713..820
FT                   /evidence="ECO:0000255"
FT   COILED          880..943
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        1602..1676
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1695..1732
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        201
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P54265,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-
FT                   ProRule:PRU10027"
FT   BINDING         83..91
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P54265,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         106
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:9418861"
FT   SITE            478..479
FT                   /note="Cleavage; by CASP3 in vitro"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   SITE            984..985
FT                   /note="Cleavage; by CASP3 in vitro"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         222
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         234
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         240
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         1127
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16641100"
FT   MOD_RES         1545
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         1611
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         1613
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         1629
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         1651
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1664
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         1669
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         1693
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         1719
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VT25"
FT   MOD_RES         1721
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MUTAGEN         106
FT                   /note="K->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:9418861"
FT   HELIX           3..16
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           18..20
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   TURN            21..23
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           28..43
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   TURN            46..49
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           51..70
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           74..76
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   STRAND          77..85
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   STRAND          87..96
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   TURN            97..99
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   STRAND          102..109
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           110..115
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   TURN            116..119
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           122..131
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   TURN            134..136
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   STRAND          140..145
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   STRAND          147..154
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           162..167
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   TURN            168..171
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           175..194
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           204..206
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   STRAND          207..209
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   STRAND          215..217
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           241..243
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           246..253
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           262..277
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           287..295
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           297..300
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           312..319
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           325..327
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   TURN            329..334
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           335..338
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           341..343
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   TURN            348..350
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           351..353
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   HELIX           397..399
FT                   /evidence="ECO:0007829|PDB:4AW2"
FT   STRAND          404..407
FT                   /evidence="ECO:0007829|PDB:4AW2"
SQ   SEQUENCE   1732 AA;  197064 MW;  65F62F7872ACCD3B CRC64;
     MSGEVRLRQL EQFILDGPAQ TNGQCFSVET LLDILICLYD ECNNSPLRRE KNILEYLEWA
     KPFTSKVKQM RLHREDFEIL KVIGRGAFGE VAVVKLKNAD KVFAMKILNK WEMLKRAETA
     CFREERDVLV NGDSKWITTL HYAFQDDNNL YLVMDYYVGG DLLTLLSKFE DRLPEEMARF
     YLAEMVIAID SVHQLHYVHR DIKPDNILMD MNGHIRLADF GSCLKLMEDG TVQSSVAVGT
     PDYISPEILQ AMEDGKGRYG PECDWWSLGV CMYEMLYGET PFYAESLVET YGKIMNHKER
     FQFPTQVTDV SENAKDLIRR LICSREHRLG QNGIEDFKKH PFFSGIDWDN IRNCEAPYIP
     EVSSPTDTSN FDVDDDCLKN SETMPPPTHT AFSGHHLPFV GFTYTSSCVL SDRSCLRVTA
     GPTSLDLDVN VQRTLDNNLA TEAYERRIKR LEQEKLELTR KLQESTQTVQ ALQYSTVDGP
     LTASKDLEIK SLKEEIEKLR KQVAEVNHLE QQLEEANSVR RELDDAFRQI KAFEKQIKTL
     QQEREELNKE LVQASERLKN QSKELKDAHC QRKLAMQEFM EINERLTELH TQKQKLARHV
     RDKEEEVDLV MQKAESLRQE LRRAERAKKE LEVHTEALIA EASKDRKLRE QSRHYSKQLE
     NELEGLKQKQ ISYSPGICSI EHQQEITKLK TDLEKKSIFY EEEISKREGI HASEIKNLKK
     ELHDSEGQQL ALNKEIMVLK DKLEKTRRES QSEREEFENE FKQQYEREKV LLTEENKKLT
     SELDKLTSLY ESLSLRNQHL EEEVKDLADK KESVAHWEAQ ITEIIQWVSD EKDARGYLQA
     LASKMTEELE ALRNSSLGTR ATDMPWKMRR FAKLDMSARL ELQSALDAEI RAKQAIQEEL
     NKVKASNIIT ECKLKDSEKK NLELLSEIEQ LIKDTEELRS EKGVEHRDSQ HSFLAFLNTP
     TDALDQFERS PSCTPAGKGR RIADSAPLPV HTPTLRKKGC PASAGFPPKR KTHQFFVKSF
     TAPTKCHQCT SLMVGLIRQG CSCEVCGFSC HITCVNKAPT TCPVPPEQTK GPLGIDPQKG
     VGTAYEGHVR IPKPAGVKKG WQRALAVVCD FKLFLYDIAE GKASQPSSVI SQVIDMRDEE
     FSVSSVLASD VIHASRKDIP CIFRVTASQL SAPSDKCSIL MLADSETERS KWVGVLSELH
     KVLKKNKFRD RSVYVPKEAY DSTLPLIKTT QAAAIIDHER VALGNEEGLF VVHVTKDEII
     RVGDNKKIHQ IELIPSDQLV AVISGRNRHV RLFPMSALDG RETDFYKLAE TKGCQTIAAG
     KVRHGALSCL CVAMKRQVLC YELFQSKTRH RKFKEIQVPC NVQWMAIFSE HLCVGFQSGF
     LRYPLNGEGS PCNMLHSNDH TLAFITHQPM DAICAVEISN KEYLLCFSSI GIYTDCQGRR
     SRQQELMWPA NPSSCCYNAP YLSIYSENAV DIFDVNSMEW IQTLPLKKVR PLNTEGSLNL
     LGLETIRLIY FKNKMAEGDE LVVPETSDNS RKQMVRNINN KRRYSFRVPE EERMQQRREM
     LRDPEMRNKL ISNPTNFNHI AHMGPGDGIQ ILKDLPMNPR PQESRTVFSG SVSIPSITKS
     RPEPGRSMSA SSGLSARSSA QNGSALKREF SGGSYNTKRQ PMPSPSEGSL SSGGVDQGSD
     APVRDYDGED SDSPRHSTAS NSSNLSSPPS PVSPRKTKSL SLESTDRGSW DP
//
